PainCeptor Pharma

From Wikipedia, the free encyclopedia

PainCeptor Pharma is a private Canadian company focused on the development of drugs that act outside the central nervous system on nociceptors to treat pain.[1] The company's strategic focus on peripheral rather than central acting therapeutics is an attempt to avoid the known side-effects of existing central acting agents.[2] The primary molecular targets addressed by PainCeptor are members of the ASIC ion channel family and nerve growth factor (NGF) and NGF receptors.[2] Though PainCeptor refers to itself as a biopharmaceutical company on its website,[1] its two primary publicly reported drug discovery projects aim to deliver small molecule therapeutics.[2]

[edit] References

  1. ^ a b PainCeptor Pharma corporate home page (HTML). PainCeptor Pharma public corporate website. Retrieved on 2007-10-18.
  2. ^ a b c Dimond, Patricia F.. "Revamping Drug Discovery Strategies", Drug Discovery, Genetic Engineering News, 2007-10-01. Retrieved on 2007-10-18. 

[edit] External links

 This article about a Canadian corporation or company is a stub. You can help Wikipedia by expanding it.